title: Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
abstract: Accumulated data from animal models and human cancer patients strongly support the concept that the immune system can identify and control nascent tumor cells in a process called cancer immunosurveillance. In addition, the immune system can also promote tumor progression through chronic inflammation, immunoselection of poorly immunogenic variants, and suppressing antitumor immunity. Together, the dual host-protective and tumor-promoting actions of immunity are referred to as cancer immunoediting. The current framework of cancer immunoediting is a dynamic process comprised of three distinct phases: elimination, equilibrium, and escape. Recently, we demonstrated that immunoselection by CD8(+) T cells of tumor variants lacking strong tumor-specific antigens represents one mechanism by which cancer cells escape tumor immunity and points toward the future of personalized cancer therapy.
authors: Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.
authors: Matthew D
authors: MD
authors: Vesely
authors: Robert D
authors: RD
authors: Schreiber
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology; D018076:DNA, Complementary / Q000378:metabolism; D004195:Disease Models, Animal; D014644:Genetic Variation; D023281:Genomics; D006801:Humans; D007157:Immunologic Surveillance / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013049:Spectrin / Q000235:genetics
chemical_list: D000951:Antigens, Neoplasm; D018076:DNA, Complementary; C452439:SPTBN1 protein, human; D013049:Spectrin
references: Nature. 2001 Apr 26;410(6832):1107-11
references: 11323675
references: Science. 2011 Mar 25;331(6024):1553-8
references: 21436442
references: Nature. 2012 Feb 08;482(7385):405-9
references: 22318517
references: Annu Rev Immunol. 2011;29:235-71
references: 21219185
references: Cancer Res. 2008 Feb 1;68(3):889-92
references: 18245491
references: Science. 2007 Nov 16;318(5853):1108-13
references: 17932254
references: Nature. 2007 Dec 6;450(7171):903-7
references: 18026089
references: Nat Immunol. 2002 Nov;3(11):999-1005
references: 12407407
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Nature. 2012 Feb 08;482(7385):400-4
references: 22318521